Home Covid-19 pandemic: Wave of promising study results raises hopes for coronavirus vaccines...
Array

Covid-19 pandemic: Wave of promising study results raises hopes for coronavirus vaccines – health


Early data from trials of three potential COVID-19 vaccines released on Monday, including a closely-watched candidate from Oxford University, increased confidence that a vaccine can train the immune system to recognize and fight the novel coronavirus without serious side effects.

Whether any of these efforts will result in a vaccine capable of protecting billions of people and ending the global pandemic that has claimed more than 600,000 lives is still far from clear. All will require much larger studies to prove they can safely prevent infection or serious disease.

The vaccine being developed by British drugmaker AstraZeneca along with the Oxford University, induced an immune response in all study participants who received two doses without any worrisome side effects.

A coronavirus vaccine under development by CanSinoBiologics Inc and China’s military research unit, likewise showed that it appears to be safe and induced an immune response in most of the 508 healthy volunteers who got one dose of the vaccine, researchers reported.

Some 77% of study volunteers experienced side effects like fever or injection site pain, but none considered to be serious.

Both the AstraZeneca and CanSino vaccines use a harmless cold virus known as an adenovirus to carry genetic material from the novel coronavirus into the body. Studies on both vaccines were published in the journal The Lancet.

“Overall, the results of both trials are broadly similar and promising,” Naor Bar-Zeev and William Moss, two vaccine experts from Johns Hopkins Bloomberg School of Public Health, wrote in a commentary in The Lancet.

However, the CanSino candidate again showed signs that people who had previously been exposed to the particular adenovirus in its vaccine had a reduced immune response.

The study authors called that “the biggest obstacle” for the vaccine to overcome.

German biotech BioNTech and U.S. drugmaker Pfizer Inc released details from a small study in Germany of a different type of vaccine that uses ribonucleic acid (RNA) – a chemical messenger that contains instructions for making proteins.

The vaccine instructs cells to make proteins that mimic the outer surface of the coronavirus. The body recognizes these virus-like proteins as foreign invaders and can then mount an immune response against the actual virus.

In the not-yet peer reviewed study of 60 healthy adults, the vaccine induced virus-neutralizing antibodies in those given two doses, a result in-line with a previous early-stage U.S. trial. The burst of announcements followed publication last week of results of Moderna Inc’s vaccine trial, showing similarly promising early results. Moderna’s vaccine also uses a messenger RNA platform.

“It’s encouraging that all these vaccines seem to induce antibodies in people,” said former World Health Organization (WHO) assistant director-general Marie-Paule Kieny of the French research institute Inserm. “This proves that the science is moving forward very quickly, which is a good sign.”

‘LONG WAY TO GO’

None of these leading contenders has shown side effects that could sideline their efforts so far, but all must still prove they are safe and effective in trials involving thousands of subjects, including those at high-risk for severe COVID-19, such as the elderly and people with diabetes.

Historically, just 6% of vaccine candidates end up making it to market, often after a years-long testing process. Vaccine makers hope to dramatically compress that timeline through faster trials and by manufacturing at scale even before the products prove successful.

Several manufacturers have U.S. government backing with a goal of having a coronavirus vaccine by year’s end as cases continue to rise at a record pace.

The Oxford/AstraZeneca vaccine is one of 150 in development globally, but is considered the most advanced. Late-stage trials have begun in Brazil and South Africa and are due to start in the United States, where the infection prevalence is highest.

In its Phase I trial, the vaccine induced so-called neutralizing antibodies – the kind that stop the virus from infecting cells – in 91% of individuals a month after they got one dose, and in 100% of subjects who got a second dose. These levels were on par with the antibodies produced by people who survived COVID-19 – a key benchmark of potential success.

Oxford researcher Sarah Gilbert said the trial could not determine whether one or two doses would be needed to provide immunity.

The vaccine, known as AZD1222, also induced the body to make T cells – activating a second part of the immune system that experts increasingly believe will be important for a lasting immune response.

Recent studies show that some recovered patients who tested negative for coronavirus antibodies developed T cells in response to their infection. Scientists think both are important aspects of an effective coronavirus vaccine.

Dr Mike Ryan, head of WHO’s emergencies program, said the generation of both T-cell and neutralizing antibody responses was positive, adding, “there is a long way to go.”

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)

Follow more stories on Facebook and Twitter





Source by [author_name]

Stay tune

110FansLike
400FollowersFollow

Most Popular

“The poor in India are hungry because…,” Rahul Gandhi targeted the...

India ranks 94th in global malnutrition index A report on this was published recently. India was ranked 102nd out of 117 countries...

Live broadcast of Ramlila from Ayodhya on DD National from today

Ramlila's program will be telecast live on DD National. It will be telecast live from October 17 to 25 from 7 pm,...

The father killed his daughter out of interracial love affair

Murdered and buried her body in a Farm. A young woman was murdered by her father and two...

In India, a plan to vaccinate 300 million people in the...

Vaccine production against the corona virus is at a critical stage. Who should be India's first priority in vaccination? They have begun...

Mithun Chakraborty’s son charged with rape; He also lodged a complaint...

Gemini's wife threatens victim? A complaint has been lodged at the Oshiwara police station against actor Mithun Chakraborty's...

Grab This Awesome Deals . Why This BoAt Rockerz 255 Sports...

Every one is now music addicted And get very cautious about their electronic gadgets . But peoples are very confused for those...

Transport Minister Anil Parab corona positive, admitted to Lilavati Hospital

Transport Minister Anil Parab has been hit by the corona. He has been admitted to Lilavati Hospital and is undergoing treatment. Till...

Bold and hot Mallika’s ‘fitness’ Inspiring Story From Instagram

Hot and bold actress Mallika Sherawat Fitness Photos Hot and bold actress Mallika Sherawat has posted a photo of...